2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Ganglion Cysts D045888 1 associated lipids
Fetal Nutrition Disorders D048070 1 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Acute Pain D059787 3 associated lipids
Head Injuries, Closed D016489 5 associated lipids
Brain Concussion D001924 5 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Hepatic Encephalopathy D006501 9 associated lipids
Morphine Dependence D009021 9 associated lipids
Hyperkinesis D006948 11 associated lipids
Fatty Liver, Alcoholic D005235 11 associated lipids
Encephalitis D004660 15 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Hypothermia D007035 19 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Brain Edema D001929 20 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Llorente R et al. Gender-dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: a possible role for the endocannabinoid system. 2008 Dev Neurobiol pmid:18666205
Nomura DK et al. Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. 2008 Bioorg. Med. Chem. Lett. pmid:18752948
DiPatrizio NV and Simansky KJ Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. 2008 J. Neurosci. pmid:18815256
Baldassarri S et al. The endocannabinoid 2-arachidonoylglycerol activates human platelets through non-CB1/CB2 receptors. 2008 J. Thromb. Haemost. pmid:18647220
Shiratsuchi A et al. Involvement of cannabinoid receptor CB2 in dectin-1-mediated macrophage phagocytosis. 2008 Immunol. Cell Biol. pmid:17909562
Duan Y et al. Inhibition of [3H]batrachotoxinin A-20alpha-benzoate binding to sodium channels and sodium channel function by endocannabinoids. 2008 Neurochem. Int. pmid:17888543
Rimmerman N et al. Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. 2008 Br. J. Pharmacol. pmid:17965731
Hill MN et al. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus. 2008 Hippocampus pmid:18058925
Maccarrone M et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. 2008 Nat. Neurosci. pmid:18204441
Hashimotodani Y et al. Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release. 2008 Neuropharmacology pmid:17655882
Mátyás F et al. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. 2008 Neuropharmacology pmid:17655884
Shimizu T and Yokotani K Bidirectional roles of the brain 2-arachidonoyl-sn-glycerol in the centrally administered vasopressin-induced adrenomedullary outflow in rats. 2008 Eur. J. Pharmacol. pmid:18234185
Engeli S et al. Peripheral endocannabinoid system activity in patients treated with sibutramine. 2008 Obesity (Silver Spring) pmid:18356837
Oláh M et al. The role of endocannabinoids in the regulation of luteinizing hormone and prolactin release. Differences between the effects of AEA and 2AG. 2008 Mol. Cell. Endocrinol. pmid:18308464
Hill MN et al. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. 2008 Pharmacopsychiatry pmid:18311684
Palkovits M et al. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. 2008 Neuroscience pmid:18343585
Nomura DK et al. Activation of the endocannabinoid system by organophosphorus nerve agents. 2008 Nat. Chem. Biol. pmid:18438404
Bisogno T Endogenous cannabinoids: structure and metabolism. 2008 J. Neuroendocrinol. pmid:18426492
Rubio M et al. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. 2008 Neuropharmacology pmid:18371990
Di Marzo V and Maccarrone M FAAH and anandamide: is 2-AG really the odd one out? 2008 Trends Pharmacol. Sci. pmid:18394720
Solinas M et al. The endocannabinoid system in brain reward processes. 2008 Br. J. Pharmacol. pmid:18414385
Richardson D et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. 2008 Arthritis Res. Ther. pmid:18416822
Ruby MA et al. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. 2008 Proc. Natl. Acad. Sci. U.S.A. pmid:18794527
Ortar G et al. Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. 2008 J. Med. Chem. pmid:18831576
Palmer JA et al. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. 2008 Neuroscience pmid:18541380
Hoover HS et al. Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. 2008 Bioorg. Med. Chem. Lett. pmid:18657971
Di Marzo V Endocannabinoids: synthesis and degradation. 2008 Rev. Physiol. Biochem. Pharmacol. pmid:18481028
Pertwee RG Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. 2008 Addict Biol pmid:18482430
Di Filippo M et al. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. 2008 J. Neurol. Neurosurg. Psychiatr. pmid:18535023
Awumey EM et al. Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries. 2008 Am. J. Physiol. Heart Circ. Physiol. pmid:18375719
Hill MN et al. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. 2008 J Neural Transm pmid:18974922
Ellgren M et al. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. 2008 Eur Neuropsychopharmacol pmid:18674887
Fowler CJ and Ghafouri N Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? 2008 Pharmacol. Res. pmid:18675915
Fowler CJ "The tools of the trade"--an overview of the pharmacology of the endocannabinoid system. 2008 Curr. Pharm. Des. pmid:18781976
Placzek EA et al. Mechanisms for recycling and biosynthesis of endogenous cannabinoids anandamide and 2-arachidonylglycerol. 2008 J. Neurochem. pmid:18778304
Placzek EA et al. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. 2008 Neuropharmacology pmid:18760289
Qin N et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. 2008 J. Neurosci. pmid:18550765
Lehtonen M et al. Mass-spectrometric identification of anandamide and 2-arachidonoylglycerol in nematodes. 2008 Chem. Biodivers. pmid:19035572
Endsley MP et al. Expression and function of fatty acid amide hydrolase in prostate cancer. 2008 Int. J. Cancer pmid:18566995
Rockwell CE et al. A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells. 2008 Biochem. Pharmacol. pmid:18571623
Njie YF et al. Aqueous humor outflow effects of 2-arachidonylglycerol. 2008 Exp. Eye Res. pmid:18597752
Motaghedi R and McGraw TE The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. 2008 Obesity (Silver Spring) pmid:18551116
Burston JJ et al. N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. 2008 J. Pharmacol. Exp. Ther. pmid:18682568
Avraham Y et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist, in various rat tissues during the evolution of experimental cholestatic liver disease. 2008 Jul-Aug Prostaglandins Leukot. Essent. Fatty Acids pmid:18771906
Marco EM and Viveros MP The critical role of the endocannabinoid system in emotional homeostasis: avoiding excess and deficiencies. 2009 Mini Rev Med Chem pmid:19929814
Alvarez-Jaimes L et al. Chronic ethanol treatment potentiates ethanol-induced increases in interstitial nucleus accumbens endocannabinoid levels in rats. 2009 J. Neurochem. pmid:19650871
Straiker A et al. Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. 2009 Mol. Pharmacol. pmid:19767452
Bisogno T et al. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. 2009 Biochim. Biophys. Acta pmid:19027877
Long JZ et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. 2009 Nat. Chem. Biol. pmid:19029917
Koppel J et al. Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. 2009 Lipids Health Dis pmid:19144193